Mon Sep 23 22:02:12 UTC 2024: ## Akero Therapeutics’ Chief Development Officer Sells Shares Amidst Phase 3 Trial Advancements

**Akero Therapeutics, Inc. (NASDAQ:AKRO) has recently seen notable insider trading activity, with Chief Development Officer Yale Catriona selling over $150,000 worth of shares on September 20, 2024.** The transaction was executed under a pre-arranged 10b5-1 trading plan and involved the sale of 5,500 shares at an average price of $27.652 per share.

**However, the same day, Catriona also acquired 5,500 shares of Akero Therapeutics common stock at a price of $0.615 per share, totaling $3,382.50.** This purchase was also conducted under the terms of a 10b5-1 trading plan.

**These transactions come as Akero Therapeutics continues to make strides in its Phase 3 trial for a treatment targeting MASH patients with compensated cirrhosis.** The trial, named SYNCHRONY Outcomes, evaluates the efficacy of efruxifermin (EFX) in patients with fibrosis stage 4 (F4). Akero has all three Phase 3 trials of EFX underway, and the company’s positive outlook has been reinforced by H.C. Wainwright’s maintained “Buy” rating.

**The SYNCHRONY trial plans to enroll approximately 1,150 F4 MASH patients, who will receive weekly injections of either 50 mg EFX or a placebo.** The trial’s first cohort will focus on assessing fibrosis regression without worsening of MASH after a 96-week treatment period.

**Investors are eagerly awaiting the Week 96 data release from the ongoing Phase 2b SYMMETRY study, expected in the first quarter of 2025.** This data will offer insights into the long-term effects of EFX on F4 MASH patients and is seen as a critical near-term milestone for Akero and its EFX treatment.

**While Akero Therapeutics’ recent insider trading activity and trial developments offer insights into the company’s trajectory, investors are advised to consider the company’s financial metrics and analyst expectations.**

**InvestingPro data indicates that Akero Therapeutics currently holds a market capitalization of approximately $1.95 billion.** However, the company’s P/E ratio stands at -8.29, reflecting expectations of negative earnings. This is further supported by the adjusted P/E ratio for the last twelve months as of Q2 2024, which is at -9.5. Additionally, the company’s EBITDA growth during the same period has significantly decreased by 86.07%, with a Return on Assets at -26.71%. These figures suggest challenging operational performance.

**Despite these hurdles, the company has shown a strong return over the last three months, with a price total return of 22.28%.** This performance could be indicative of investor optimism or a reaction to specific company developments that may not be fully captured by traditional financial metrics.

**For a deeper dive into Akero Therapeutics’ performance and future outlook, investors can access additional insights on the InvestingPro platform.**

Read More